

Supplementary Table S1. AML primary samples information

#	Type	Gen	Age (yr)	WHO subtype	WBC, x10 <sup>9</sup> cells/L	% Blasts PB	% Blasts BM	Karyotype	Additional molecular features	Risk
#61	LA	M	48	AML, NOS	131	63	81	46,XY	N/D	Int
#63	LA	F	44	AML with mutated <i>NPM1</i>	159	76	80	N/A	<i>NPM1</i> mut	Fav
#98	LA	F	63	AML with mutated <i>NPM1</i>	384	100	94	N/A	<i>FLT3</i> -ITD, <i>DNMT3A</i> mut, <i>IDH2</i> mut	Int
#130	LA	M	47	AML with mutated <i>NPM1</i>	118	23	48	46,XY	<i>DNMT3A</i> mut, <i>IDH2</i> mut, <i>TP53</i> mut	Adv
#132	PB	M	61	AML with myelodysplasia related changes	41.1	N/A	16	41,X-Y,add(1)(p34),add(2)(p25),-3,-3,-5,add(6)(p25),-7,-12,add(16)(q24),-17,-18,-21,+4mar[cp20]	<i>TP53</i> mut	Adv
#133	LA	M	40	AML with mutated <i>NPM1</i>	109	96	93	N/A	<i>IDH1</i> mut, <i>NPM1</i> mut, <i>FLT3</i> -ITD	Int
#134	LA	M	37	AML with inv(16)(p13.1q22); <i>CBFB-MYH11</i>	295	98	91	47,XY,+9,inv(16)(p13;q22),der(17)t(11;17)(q13;q25)	<i>CEBPA</i> mut, <i>FLT3</i> -N676K, <i>WT1</i> mut	Fav
#135	PB	M	28	AML with t(8;21)(q22;q22); <i>RUNX1-RUNX1T1</i>	45	83	79	47,XY,t(8;21)(q22;q22),+8[5]/46,XY[17]	<i>RB1</i> mut	Fav
#136	PB	F	43	AML with biallelic mutations of <i>CEBPA</i>	7	74	51	46,XY	<i>CEBPA</i> mut, <i>WT1</i> mut, <i>TET2</i> mut	Fav
#141	LA	M	65	AML with mutated <i>NPM1</i>	107	62	80	46,XY	<i>NPM1</i> mut, <i>FLT3</i> -ITD	Fav
#147	BM	F	74	AML with biallelic mutations of <i>CEBPA</i>	3.2	20	23	46,XX	<i>CEBPA</i> mut, <i>TET2</i> mut	Fav
#148	BM	M	48	AML, NOS without maturation	40	95	85	47,XY,+11[13]/46,XY[7]	<i>IDH2</i> mut, <i>DNMT3A</i> mut, <i>NF1</i> mut	Int
#152	PB	M	84	AML with myelodysplasia related changes	36	84	66	46,XY,del(20)(q11q13)[5]/48,XY,+8,del(20)(q11q13),+21[15]	<i>JAK2</i> mut, <i>IDH2</i> mut, <i>SRSF2</i> mut, <i>ETV6-MN1</i>	Int
#153	BM	M	72	AML with mutated <i>NPM1</i>	3.5	16	38	46,XY	<i>NPM1</i> mut, <i>FLT3</i> -ITD, <i>IDH2</i> mut, <i>RUNX1</i> mut, <i>WT1</i> mut, <i>IDH1</i> mut, <i>DNMT3A</i> mut	Fav

\*Adv indicates adverse; BM, bone marrow; F, female; Fav, favorable; Gen, gender; int, intermediate; LA, leukapheresis; M, male; WBC, white blood cells count; WHO, World Health Organization; yr, years